IND-Enabling Safety Studies for ART5803, a Clinical-Stage Therapeutic One-Armed Antibody to Treat Anti-NMDA Receptor Encephalitis (S7.004)

20250 citationsJournal Article

Authors

Mitsuyuki Matsumoto · Elusys Therapeutics (United States)

Amir S. Razai · Elusys Therapeutics (United States)

Scott J. Snipas · Elusys Therapeutics (United States)

Shanni Yamaki · Elusys Therapeutics (United States)

Roghiye Kazimi · Elusys Therapeutics (United States)

Vallari R. Eastman · Elusys Therapeutics (United States)

Mari Maurer

Abstract

To assess the safety profile of ART5803, a therapeutic one-armed antibody to block the pathogenicity of anti-NMDA receptor (NMDAR) autoantibodies (autoAbs) in patients with anti-NMDAR encephalitis (ANRE).

Topics & Keywords

Autoimmune Neurological Disorders and Treatments Neuroscience and Neuropharmacology Research Genetics and Neurodevelopmental Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 104, Issue 7_Supplement_1

DOI: 10.1212/wnl.0000000000208619

Field-Weighted Citation Impact: 0.00